SecBot SecBot

RLAY

Relay Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001812364 Biotech & Drug Discovery
$17.27 −0.82 (−4.53%)
Nov 16 4:00 PM ET · prev $18.09
Market cap
$4.0B
Mid cap
Consensus
Buy
95% Buy or better · 19 analysts
Median target
$29.00
+68% · range $25.00–32.00
1 year
+160.9%
from $6.62 · Nov 17
30 days
+1.1%
from $17.09
52-week range
$6.34–20.75
−17% from high · low Nov 19
Avg volume 20D
2.56M
shares / day
Short interest
43.63M
≈19.8% of shares · −0.9%
Days to cover
20.7
at average volume
Insider net
−$128.5M
0 buyers · 5 sellers · 12 mo
New fund stakes
4
Q2 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 2 bearish · 0 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 3/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • Apr 7 to Apr 9 ▼ 2 days of insider sells: $257.5K by 1 insider, avg $13.19
  • Apr 27 ▲ Relay Therapeutics announced positive clinical data from the zovegal…
  • May 21 Activist stake: Relay Therapeutics Announces Pricing of Public Offering of…
  • Jun 30 ▲ 4 funds open new positions (13F)
  • Jun 30 to Jul 7 ▼ 3 days of insider sells: $2.4M by 4 insiders, avg $19.20
  • Jul 16 Canaccord Genuity initiates
  • Jul 28 ▼ 3 insiders sell $82.7K at $18.61
  • Aug 14 to Aug 17 ▼ 2 days of insider sells: $1.3M by 2 insiders, avg $20.17
  • Aug 25 to Aug 26 ▼ 2 days of insider sells: $116.5M by 2 insiders, avg $19.40
  • Sep 8 ▼ 3 insiders sell $1.4M at $18.94
  • Oct 6 to Oct 7 ▼ 2 days of insider sells: $1.2M by 2 insiders, avg $18.23
  • Oct 28 ▼ 3 insiders sell $83.3K at $18.62

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $128.5M.

  • InstitutionsBULLISH

    Q2 2026: 48 added (4 new), 15 trimmed or exited. Largest new: Westfield Capital Management $62.6M, Polar Capital Holdings $33.5M.

  • AnalystsBULLISH

    18 of 19 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.380 → −$0.354 over 90 days. 5 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −0.9% to 43.63M shares. 20.7 days to cover, ≈19.8% of shares.

  • TrendRANGE

    6% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 1.

Who's buying

13F· Q2 2026
4
new positions
0
exits
$129.6M
in new stakes
FundMoveSharesValue
FMR LLCDOUBLED20,110,113$376.3M
STATE STREET CORPADD10,125,381$189.5M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED7,708,507$144.2M
GEODE CAPITAL MANAGEMENT, LLCADD4,726,576$88.4M
MORGAN STANLEYDOUBLED3,851,071$72.1M
GOLDMAN SACHS GROUP INCADD3,408,701$63.8M
WESTFIELD CAPITAL MANAGEMENT CO LPNEW3,343,496$62.6M
VANGUARD PORTFOLIO MANAGEMENT LLCADD2,892,785$54.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 95% rate it Buy or better
Strong Buy7Buy11Hold1Sell0Strong Sell0
12-month targets · 12 analysts

Price is below the lowest target. Median implies +68%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026Jones Trading
MAINTAIN
MAINTAINBuy
Aug 20, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 14, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 10, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Aug 7, 2026Barclays
MAINTAIN
MAINTAINOverweight
Jul 21, 2026Goldman Sachs
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$128.5M
sold · 5 insiders
DateInsiderTypeValue
Oct 28, 2026
Bergstrom Donald A
President, R&D
Oct 28, 2026
SELL$41.9K
Oct 28, 2026
Catinazzo Thomas
Chief Financial Officer
Oct 28, 2026
SELL$27.4K
Oct 28, 2026
Rahmer Peter
See remarks
Oct 28, 2026
SELL$14.0K
Oct 7, 2026
Patel Sanjiv
President and CEO
Oct 7, 2026
SELL$872.4K
Oct 6, 2026
Catinazzo Thomas
Chief Financial Officer
Oct 6, 2026
SELL$325.4K
Oct 6, 2026
Catinazzo Thomas
Chief Financial Officer
Oct 6, 2026
SELL$4.0K
Sep 8, 2026
Bergstrom Donald A
President, R&D
Sep 8, 2026
SELL$161.8K
Sep 8, 2026
Patel Sanjiv
President and CEO
Sep 8, 2026
SELL$912.9K

Earnings setup

Estimates
−$0.35
EPS estimate, this quarter
+7%
estimate change, 90 days
5↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.35-$0.40–-$0.26+6.7%$5.9M
Next Q-$0.38-$0.41–-$0.35+2.5%$720.0K
Current FY-$1.56-$1.64–-$1.44+3.6%$6.9M
Next FY-$1.57-$1.80–-$1.15+3.7%$10.6M
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
43,629,223
shares short
-0.9%
vs prior settlement
20.7
days to cover
≈19.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 4, 2026 SEC
Relay Therapeutics reported Q3 2026 net loss of $81.7M ($0.37 per share), narrower than the consensus estimate of…
8-K · Impact 4/10
Nov 4, 2026 SEC
Relay Therapeutics reported Q3 2026 net loss of $81.7M ($0.37 per share), narrower than the $0.43 loss per share in Q3…
PRESS-RELEASE · Impact 4/10
Nov 4, 2026 Earnings
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027
Oct 28, 2026 Insider
Bergstrom Donald A sold 2,252 shares
President, R&D @ $18.62 ($41.9K)
Oct 28, 2026 Insider
Catinazzo Thomas sold 1,469 shares
Chief Financial Officer @ $18.62 ($27.4K)
Oct 28, 2026 Insider
Rahmer Peter sold 753 shares
See remarks @ $18.62 ($14.0K)
Jun 30, 2026 Inst.
FMR LLC · DOUBLED
20,110,113 shares ($376.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 4, 2026
Earnings
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027
Nov 4, 2026
Earnings result
RLAY Q3 2026 Earnings: EPS $-0.37 (+8.5% vs est)
Nov 2, 2026
Press release
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine…
Oct 28, 2026
Earnings
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine…
Sep 18, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Lifyorli, relacorilant, Status: Opinion
Human medicines European public assessment report (EPAR): Lifyorli, relacorilant, Status: Opinion

SecBot reports

15 filings · 5 press releases · 2 bullish · 4 bearish · 9 neutral
All RLAY filing & press-release reports (20)